S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
The Last Great Value Stock (Ad)pixel
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
The Last Great Value Stock (Ad)pixel
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
The Last Great Value Stock (Ad)pixel
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
The Last Great Value Stock (Ad)pixel
NASDAQ:SGRY

Surgery Partners - SGRY Stock Forecast, Price & News

$37.00
+0.10 (+0.27%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$35.03
$37.92
50-Day Range
$27.55
$40.30
52-Week Range
$26.66
$63.87
Volume
186,913 shs
Average Volume
484,199 shs
Market Capitalization
$3.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.67

Surgery Partners MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
58.6% Upside
$58.67 Price Target
Short Interest
Bearish
10.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Surgery Partners in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$1.05 M Sold Last Quarter
Proj. Earnings Growth
516.67%
From $0.06 to $0.37 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

799th out of 1,293 stocks

General Medical & Surgical Hospitals Industry

5th out of 5 stocks

SGRY stock logo

About Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on SGRY shares. Royal Bank of Canada reduced their target price on shares of Surgery Partners from $65.00 to $62.00 and set an "outperform" rating for the company in a report on Wednesday, August 3rd. Benchmark raised their target price on Surgery Partners from $65.00 to $72.00 in a report on Wednesday, May 4th. StockNews.com cut Surgery Partners from a "hold" rating to a "sell" rating in a research report on Tuesday, July 26th. Bank of America cut shares of Surgery Partners from a "buy" rating to a "neutral" rating and cut their target price for the stock from $55.00 to $36.00 in a research note on Wednesday, June 15th. Finally, Citigroup raised their price target on shares of Surgery Partners from $61.00 to $64.00 in a research note on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $58.67.

Surgery Partners Stock Up 0.3 %

Shares of SGRY Stock traded up $0.10 during trading on Monday, hitting $37.00. 183,134 shares of the company were exchanged, compared to its average volume of 484,174. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.39 and a current ratio of 1.51. Surgery Partners has a twelve month low of $26.66 and a twelve month high of $63.87. The business's 50-day simple moving average is $33.85 and its 200 day simple moving average is $44.22.

Insider Buying and Selling

In other news, insider George Goodwin sold 12,586 shares of the company's stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $40.00, for a total value of $503,440.00. Following the sale, the insider now directly owns 31,806 shares in the company, valued at approximately $1,272,240. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders sold 26,380 shares of company stock valued at $1,053,599. Insiders own 3.30% of the company's stock.

Receive SGRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surgery Partners and its competitors with MarketBeat's FREE daily newsletter.

SGRY Stock News Headlines

Surgery Partners (NASDAQ:SGRY) PT Lowered to $62.00
Recap: Surgery Partners Q2 Earnings
StockNews.com Lowers Surgery Partners (NASDAQ:SGRY) to Sell
See More Headlines
Receive SGRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surgery Partners and its competitors with MarketBeat's FREE daily newsletter.

SGRY Company Calendar

Last Earnings
11/02/2021
Today
8/08/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
General medical & surgical hospitals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SGRY
Employees
10,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$58.67
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+58.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-70,900,000.00
Pretax Margin
5.37%

Debt

Sales & Book Value

Annual Sales
$2.23 billion
Cash Flow
$1.02 per share
Book Value
$22.05 per share

Miscellaneous

Free Float
86,967,000
Market Cap
$3.33 billion
Optionable
Optionable
Beta
2.87














SGRY Stock - Frequently Asked Questions

Should I buy or sell Surgery Partners stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surgery Partners in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SGRY shares.
View SGRY analyst ratings
or view top-rated stocks.

What is Surgery Partners' stock price forecast for 2022?

7 brokerages have issued 1-year price objectives for Surgery Partners' shares. Their SGRY share price forecasts range from $36.00 to $73.00. On average, they expect the company's stock price to reach $58.67 in the next twelve months. This suggests a possible upside of 58.6% from the stock's current price.
View analysts price targets for SGRY
or view top-rated stocks among Wall Street analysts.

How has Surgery Partners' stock price performed in 2022?

Surgery Partners' stock was trading at $53.41 at the start of the year. Since then, SGRY stock has decreased by 30.7% and is now trading at $37.00.
View the best growth stocks for 2022 here
.

When is Surgery Partners' next earnings date?

Surgery Partners is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our SGRY earnings forecast
.

How were Surgery Partners' earnings last quarter?

Surgery Partners, Inc. (NASDAQ:SGRY) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.04. The company had revenue of $559.20 million for the quarter, compared to the consensus estimate of $554.15 million. Surgery Partners had a negative net margin of 1.23% and a negative trailing twelve-month return on equity of 0.61%. During the same period last year, the firm posted ($0.59) EPS.

What guidance has Surgery Partners issued on next quarter's earnings?

Surgery Partners updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.50 billion-$2.60 billion, compared to the consensus revenue estimate of $2.56 billion.

What is Eric Evans' approval rating as Surgery Partners' CEO?

7 employees have rated Surgery Partners Chief Executive Officer Eric Evans on Glassdoor.com. Eric Evans has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Surgery Partners own?

What is Surgery Partners' stock symbol?

Surgery Partners trades on the NASDAQ under the ticker symbol "SGRY."

Who are Surgery Partners' major shareholders?

Surgery Partners' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (1.18%), Cannell & Co. (0.40%), Rheos Capital Works Inc. (0.19%), TD Asset Management Inc. (0.11%), Level Four Advisory Services LLC (0.02%) and Polianta Ltd (0.02%). Insiders that own company stock include Anthony Taparo, David T Doherty, George Goodwin, Jason Eric Evans, Jennifer Baldock, Laura L Brocklehurst, Laura L Brocklehurst, Teresa Deluca, Thomas F Cowhey and Wayne S Deveydt.
View institutional ownership trends
.

How do I buy shares of Surgery Partners?

Shares of SGRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surgery Partners' stock price today?

One share of SGRY stock can currently be purchased for approximately $37.00.

How much money does Surgery Partners make?

Surgery Partners (NASDAQ:SGRY) has a market capitalization of $3.33 billion and generates $2.23 billion in revenue each year. The company earns $-70,900,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Surgery Partners have?

Surgery Partners employs 10,900 workers across the globe.

How can I contact Surgery Partners?

Surgery Partners' mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The official website for the company is www.surgerypartners.com. The company can be reached via phone at (615) 234-5900, via email at ir@surgerypartners.com, or via fax at 615-234-5998.

This page (NASDAQ:SGRY) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.